

of significant SNPs were closely linked with *HLA-B*5801* (Table 6). Previous studies have indicated that a SNP (rs2395029) in the *HCP5*, which is on 6p21.3, is strongly associated with human immunodeficiency virus-1 set points,^{28–30} abacavir-induced hypersensitivity^{24–26} and flucloxacillin-induced liver injury.³¹ This SNP is in strong LD with *HLA-B*5701* in Caucasians.²⁵ Another SNP in 6p21 in *PSORS1C1*, a psoriasis-susceptibility candidate gene, was related with psoriasis in Swedish and Canadian populations^{17,18} and exhibits LD with *HLA-Cw*0602* in Canadian populations.¹⁸ These reports suggest that SNPs located in 6p21 link with a specific type of classical class I *HLA* that could be an alternative biomarker for the physiological phenomenon. Therefore, we examined the LD between these SNPs, shown in Table 2, and *HLA-B*5801*, which has been regarded as a genetic biomarker of SJS/TEN not only in Han Chinese,⁷ but also in Caucasians⁹ and Japanese.¹⁰ We found that all of the Japanese patients with the allopurinol-related SJS/TEN who had the *HLA-B*5801* (10 patients) also had variant SNPs of genes that are located in 6p21, including *BAT1*, *HCP5*, *PPIAP9*, *PSORS1C1* and *HLA-B* (Table 3). The analysis of the LD coefficients between SNPs located in 6p21 and *HLA* types in the Japanese population indicated that these SNPs are in strong LD with *HLA* types (Table 5), and an absolute LD between rs9263726 in *PSORS1C1* and *HLA-B*5801* was observed in the Japanese population (Table 6). These results mean that all subjects (14 individuals including 10 with allopurinol-related SJS/TEN) who carry *HLA-B*5801* are in complete accord with all subjects with minor A allele of rs9263726 in the Japanese population. Therefore, rs9263726 in *PSORS1C1* is an alternative biomarker for *HLA-B*5801* in the Japanese population. Conventional genotyping of rs9263726 based on allelic discrimination offers several advantages over *HLA-B* typing, which is determined by genotyping of several SNPs forming the *HLA-B*5801* haplotype. Various broadly used technologies (for example, TaqMan genotyping) allow the standardized identification of two distinct alleles in one reaction tube, limiting the risk of contamination and allowing high-throughput genotyping with high sensitivity and specificity. In addition, the test is largely independent of both the performance of and interpretation by laboratory personnel. SNP genotyping is also less time consuming and cheaper than sequence-based *HLA* typing, and it does not require specialized laboratories. Therefore, the easy detection of these SNPs has a practical and economical advantage in clinical application for predicting the onset of allopurinol-related SJS/TEN. Although the previous report revealed that three SNPs in *HLA* region strongly associated with allopurinol-related SCAR in Han Chinese,⁷ the two SNPs analyzed by the Illumina Human 1M-DUO BeadChip showed only weak association in the Japanese. This ethnic difference might be due to the difference of LD.

The functional analysis of genes that carry these SNPs—including *HCP5*, *BAT1*, *PSORS1C1*, *CCHCR1*, *TCF19* and *POUSF1*—in the pathogenesis of allopurinol-related SJS/TEN might be useful for determining their relevance. *CCHCR1* is a regulator of keratinocyte proliferation or differentiation

and is overexpressed in keratinocytes in psoriatic lesions.^{20–23} *TCF19* is a potential trans-activating factor that could play an important role in the transcription of genes required for the later stages of cell cycle progression.²⁷ Possible psoriasis candidate genes near *HLA-B* include *PSORS1C1*,^{17–19} *CCHCR1*,^{22,23} and *POUSF1*.^{32,33} Mutations in *BAT1* may be associated with rheumatoid arthritis.^{34–36} *HCP5* encodes an endogenous retroviral element mainly that is expressed in immune cells and there is evidence that the SNP in this gene is protective against human immunodeficiency virus-1 infection.^{37–39} The functions and relevance of these genes suggest that the pathogenesis of allopurinol-related SJS/TEN might involve not only an immune system disorder, but also processes of cell proliferation and differentiation.

In conclusion, the results of this GWAS of allopurinol-related SJS/TEN in Japanese patients show that SNPs in genes located in 6p21, which are in LD with *HLA-B*5801*, are strongly associated with the cutaneous adverse reaction. Therefore, these SNPs, especially rs9263726, prove to be predictors for allopurinol-related SJS/TEN in Japanese, and their genes might be involved in the pathogenesis of allopurinol-related SJS/TEN. The OR of rs9263726 is extremely high from this case-control study and the typing cost of SNP is much cheaper than that of *HLA* typing. Moreover, the SJS/TEN has a very severe adverse reaction of allopurinol, which is high mortality. Therefore, we believe that the screening of rs9263726 genotype before allopurinol administration is necessary to prevent SJS/TEN in allopurinol-treated Japanese patients, although its allele frequency is very low in the Japanese. Association analyses of other ethnic populations are needed for confirming and comparing the results obtained in this study. *In vitro* functional studies of these genes are also necessary for identification of the physiological and molecular pathways leading to allopurinol-related SJS/TEN.

Conflict of interest

The authors declare no conflict of interest except one member of JPDSC, Mitsubishi Tanabe Pharma, which is a distributor of allopurinol in Japan.

Acknowledgments

We thank all the patients and physicians for their cooperation with this study. We also thank Riken Genesis for the Illumina BeadChip analysis and StaGen for the statistical analysis. This study was supported in part by a Health and Labor Science Research Grant (Research on Advanced Medical Technology) from the Ministry of Health, Labor and Welfare of Japan.

References

- 1 Wortmann RL. Gout and hyperuricemia. *Curr Opin Rheumatol* 2002; 14: 281–286.
- 2 Chung WH, Hung SI, Chen YT. Human leukocyte antigens and drug hypersensitivity. *Curr Opin Allergy Clin Immunol* 2007; 7: 317–323.
- 3 Tohkin M, Ishiguro A, Kaniwa N, Saito Y, Kurose K, Hasegawa R. Prediction of severe adverse drug reactions using pharmacogenetic biomarkers. *Drug Metab Pharmacokinet* 2010; 25: 122–133.

- 4 Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. *Arch Dermatol* 1993; **129**: 92–96.
- 5 French LE. Toxic epidermal necrolysis and Stevens Johnson syndrome: our current understanding. *Allergol Int* 2006; **55**: 9–16.
- 6 Bowman C, Delrieu O. Immunogenetics of drug-induced skin blistering disorders. Part I: perspective. *Pharmacogenomics* 2009; **10**: 601–621.
- 7 Hung SI, Chung WH, Liou LB, Chu CC, Lin M, Huang HP *et al*. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. *Proc Natl Acad Sci USA* 2005; **102**: 4134–4139.
- 8 Tassaneeyakul W, Jantararoungtong T, Chen P, Lin PY, Tiamkao S, Khunarkornsiri U *et al*. Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population. *Pharmacogenet Genomics* 2009; **19**: 704–709.
- 9 Lonjou C, Borot N, Sekula P, Ledger N, Thomas L, Halevy S *et al*. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. *Pharmacogenet Genomics* 2008; **18**: 99–107.
- 10 Kaniwa N, Saito Y, Aihara M, Matsunaga K, Tohkin M, Kurose K *et al*. HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. *Pharmacogenomics* 2008; **9**: 1617–1622.
- 11 Wilke RA, Lin DW, Roden DM, Watkins PB, Flockhart D, Zineh I *et al*. Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. *Nat Rev Drug Discov* 2007; **6**: 904–916.
- 12 Nakamura Y. Pharmacogenomics and drug toxicity. *N Engl J Med* 2008; **359**: 856–858.
- 13 Daly AK, Day CP. Genetic association studies in drug-induced liver injury. *Semin Liver Dis* 2009; **29**: 400–411.
- 14 Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D *et al*. PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am J Hum Genet* 2007; **81**: 559–575.
- 15 Zhao JH, Curtis D, Sham PC. Model-free analysis and permutation tests for allelic associations. *Hum Hered* 2000; **50**: 133–139.
- 16 Zhao JH. 2LD, GENE-COUNTING and HAP: computer programs for linkage disequilibrium analysis. *Bioinformatics* 2004; **20**: 1325–1326.
- 17 Holm SJ, Carlen LM, Mallbris L, Stahle-Backdahl M, O'Brien KP. Polymorphisms in the SEEK1 and SPR1 genes on 6p21.3 associate with psoriasis in the Swedish population. *Exp Dermatol* 2003; **12**: 435–444.
- 18 Rahman P, Butt C, Siannis F, Farewell VT, Peddle L, Pellett FJ *et al*. Association of SEEK1 and psoriatic arthritis in two distinct Canadian populations. *Ann Rheum Dis* 2005; **64**: 1370–1372.
- 19 Zhang XJ, He PP, Wang ZX, Zhang J, Li YB, Wang HY *et al*. Evidence for a major psoriasis susceptibility locus at 6p21 (PSORS1) and a novel candidate region at 4q31 by genome-wide scan in Chinese hans. *J Invest Dermatol* 2002; **119**: 1361–1366.
- 20 Suomela S, Elomaa O, Skoog T, Ala-aho R, Jeskanen L, Parssinen J *et al*. CCHCR1 is up-regulated in skin cancer and associated with EGFR expression. *PLoS One* 2009; **4**: e6030.
- 21 Tiala I, Wakkinen J, Suomela S, Puolakkainen P, Tammi R, Forsberg S *et al*. The PSORS1 locus gene CCHCR1 affects keratinocyte proliferation in transgenic mice. *Hum Mol Genet* 2008; **17**: 1043–1051.
- 22 Suomela S, Kainu K, Onkamo P, Tiala I, Himberg J, Koskinen L *et al*. Clinical associations of the risk alleles of HLA-Cw6 and CCHCR1*WWCC in psoriasis. *Acta Derm Venereol* 2007; **87**: 127–134.
- 23 Tiala I, Suomela S, Huuhtanen J, Wakkinen J, Holtta-Vuori M, Kainu K *et al*. The CCHCR1 (HCR) gene is relevant for skin steroidogenesis and downregulated in cultured psoriatic keratinocytes. *J Mol Med* 2007; **85**: 589–601.
- 24 Hughes AR, Mosteller M, Bansal AT, Davies K, Haneline SA, Lai EH *et al*. Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations. *Pharmacogenomics* 2004; **5**: 203–211.
- 25 Colombo S, Rauch A, Rotger M, Fellay J, Martinez R, Fux C *et al*. The HCP5 single-nucleotide polymorphism: a simple screening tool for prediction of hypersensitivity reaction to abacavir. *J Infect Dis* 2008; **198**: 864–867.
- 26 Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J *et al*. HLA-B*5701 screening for hypersensitivity to abacavir. *N Engl J Med* 2008; **358**: 568–579.
- 27 Teraoka Y, Naruse TK, Oka A, Matsuzawa Y, Shiina T, Iizuka M *et al*. Genetic polymorphisms in the cell growth regulated gene, SC1 telomeric of the HLA-C gene and lack of association of psoriasis vulgaris. *Tissue Antigens* 2000; **55**: 206–211.
- 28 Migueles SA, Sabbaghian MS, Shupert WL, Bettinotti MP, Marincola FM, Martino L *et al*. HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. *Proc Natl Acad Sci USA* 2000; **97**: 2709–2714.
- 29 Altfeld M, Addo MM, Rosenberg ES, Hecht FM, Lee PK, Vogel M *et al*. Influence of HLA-B57 on clinical presentation and viral control during acute HIV-1 infection. *AIDS* 2003; **17**: 2581–2591.
- 30 Fellay J, Shianna KV, Ge D, Colombo S, Ledergerber B, Weale M *et al*. A whole-genome association study of major determinants for host control of HIV-1. *Science* 2007; **317**: 944–947.
- 31 Daly AK, Donaldson PT, Bhatnagar P, Shen Y, Pe'er I, Floratos A *et al*. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. *Nat Genet* 2009; **41**: 816–819.
- 32 Oka A, Tamiya G, Tomizawa M, Ota M, Katsuyama Y, Makino S *et al*. Association analysis using refined microsatellite markers localizes a susceptibility locus for psoriasis vulgaris within a 111 kb segment telomeric to the HLA-C gene. *Hum Mol Genet* 1999; **8**: 2165–2170.
- 33 Chang YT, Hsu CY, Chou CT, Lin MW, Shiao YM, Tsai CY *et al*. The genetic polymorphisms of POU5F1 gene are associated with psoriasis vulgaris in Chinese. *J Dermatol Sci* 2007; **46**: 153–156.
- 34 Okamoto K, Makino S, Yoshikawa Y, Takaki A, Nagatsuka Y, Ota M *et al*. Identification of I kappa BL as the second major histocompatibility complex-linked susceptibility locus for rheumatoid arthritis. *Am J Hum Genet* 2003; **72**: 303–312.
- 35 Kilding R, Iles MM, Timms JM, Worthington J, Wilson AG. Additional genetic susceptibility for rheumatoid arthritis telomeric of the DRB1 locus. *Arthritis Rheum* 2004; **50**: 763–769.
- 36 Quinones-Lombrana A, Lopez-Soto A, Ballina-Garcia FJ, Alperi-Lopez M, Queiro-Silva R, Lopez-Vazquez A *et al*. BAT1 promoter polymorphism is associated with rheumatoid arthritis susceptibility. *J Rheumatol* 2008; **35**: 741–744.
- 37 van Manen D, Kootstra NA, Boeser-Nunnink B, Handulle MA, van't Wout AB, Schuitemaker H. Association of HLA-C and HCP5 gene regions with the clinical course of HIV-1 infection. *AIDS* 2009; **23**: 19–28.
- 38 Catano G, Kulkarni H, He W, Marconi VC, Agan BK, Landrum M *et al*. HIV-1 disease-influencing effects associated with ZNRD1, HCP5 and HLA-C alleles are attributable mainly to either HLA-A10 or HLA-B*57 alleles. *PLoS One* 2008; **3**: e3636.
- 39 Han Y, Lai J, Barditch-Crovo P, Gallant JE, Williams TM, Siliciano RF *et al*. The role of protective HCP5 and HLA-C associated polymorphisms in the control of HIV-1 replication in a subset of elite suppressors. *AIDS* 2008; **22**: 541–544.
- 40 Tanaka H, Akaza T, Juji T. Report of the Japanese Central Bone Marrow Data Center. *Clin Transpl* 1996; **9**: 139–144.
- 41 Tokunaga K, Ishikawa Y, Ogawa A, Wang H, Mitsunaga S, Moriyama S *et al*. Sequence-based association analysis of HLA class I and II alleles in Japanese supports conservation of common haplotypes. *Immunogenetics* 1997; **46**: 199–205.

Appendix

Japan Pharmacogenomics Data Science Consortium (JPDSC)

The Japan Pharmacogenomics Data Science Consortium is composed of Astellas Pharma, Otsuka Pharmaceutical,

Daiichi Sankyo, Taisho Pharmaceutical, Takeda Pharmaceutical and Mitsubishi Tanabe Pharma, and is chaired by Ichiro Nakaoka (Takeda Pharmaceutical).

Visual Improvement after Cultivated Oral Mucosal Epithelial Transplantation

Chie Sotozono, MD, PhD,¹ Tsutomu Inatomi, MD, PhD,¹ Takahiro Nakamura, MD, PhD,¹ Noriko Koizumi, MD, PhD,¹ Norihiko Yokoi, MD, PhD,¹ Mayumi Ueta, MD, PhD,¹ Kotone Matsuyama, BS,² Keiko Miyakoda, MS, MPH,² Hideaki Kaneda, MD, PhD,² Masanori Fukushima, MD, PhD,² Shigeru Kinoshita, MD, PhD¹

Purpose: To report the effectiveness, disease-specific outcomes, and safety of cultivated oral mucosal epithelial sheet transplantation (COMET), with the primary objective of visual improvement.

Design: Noncomparative, retrospective, interventional case series.

Participants: This study involved 46 eyes in 40 patients with complete limbal stem cell deficiency (LSCD) who underwent COMET for visual improvement. These LSCD disorders fell into the following 4 categories: Stevens-Johnson syndrome (SJS; 21 eyes), ocular cicatricial pemphigoid (OCP; 10 eyes), thermal or chemical injury (7 eyes), or other diseases (8 eyes).

Methods: Best-corrected visual acuity (BCVA) and ocular surface grading score were examined before surgery; at the 4th, 12th, and 24th postoperative week; and at the last follow-up. Data on COMET-related adverse events and postoperative management were collected. The outcomes in each disease category were evaluated separately.

Main Outcome Measures: The primary outcome was the change in median logarithm of the minimum angle of resolution (logMAR) BCVA at the 24th postoperative week. The secondary outcome was the ocular surface grading score.

Results: Median logMAR BCVA at baseline was 2.40 (range, 1.10 to 3.00). In SJS, logMAR BCVA improved significantly during the 24 weeks after surgery. In contrast, the BCVA in OCP was improved significantly only at the 4th postoperative week. In 6 of the 7 thermal or chemical injury cases, logMAR BCVA improved after planned penetrating keratoplasty or deep lamellar keratoplasty. Grading scores of ocular surface abnormalities improved in all categories. Of 31 patients with vision loss (logMAR BCVA, >2) at baseline, COMET produced improvement (logMAR BCVA, ≤2) in 15 patients (48%). Visual improvement was maintained with long-term follow-up (median, 28.7 months). Multivariate stepwise logistic regression analysis showed that corneal neovascularization and symblepharon were correlated significantly with logMAR BCVA improvement at the 24th postoperative week ($P = 0.0023$ and $P = 0.0173$, respectively). Although postoperative persistent epithelial defects and slight to moderate corneal infection occurred in the eyes of 16 and 2 patients, respectively, all were treated successfully with no eye perforation.

Conclusions: Long-term visual improvement was achievable in cases of complete LSCD. Cultivated oral mucosal epithelial sheet transplantation offered substantial visual improvement even for patients with end-stage severe ocular surface disorders accompanying severe tear deficiency. Patients with corneal blindness such as SJS benefited from critical improvement of visual acuity.

Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article. *Ophthalmology* 2013;120:193–200 © 2013 by the American Academy of Ophthalmology.



Corneal renewal and repair are mediated by corneal epithelial stem cells situated mainly in the limbus, the narrow region between the cornea and the bulbar conjunctiva.¹ Damage or depletion of the corneal epithelial stem cells, known as limbal stem cell deficiency (LSCD), leads to conjunctival invasion that results in vascularization and scarring of the cornea with an associated profound loss of vision.¹ Limbal stem cell deficiency can be caused by Stevens-Johnson syndrome (SJS), ocular cicatricial pemphigoid (OCP), and thermal or chemical injury, which are all characterized by the loss of corneal epithelial stem cells. Such LSCD may cause severe ocular surface diseases (OSDs) in which cicatrization resulting from conjunctival fibrosis, symblepharon,

and severe dry eye greatly disrupt visual function and can progress gradually with chronic inflammation.^{2–4} To date, few effective medical or surgical treatments for severe OSDs have been available.^{5–15}

Since 1998, the authors have used amniotic membrane transplantation to treat severe OSDs. Amniotic membrane exhibits an anti-inflammatory effect and also acts as a substrate for epithelialization.¹⁶ The results of previous studies have shown that amniotic membrane transplantation alone^{17,18} or amniotic membrane transplantation combined with limbal transplantation^{6,19,20} promoted epithelialization, reduced pain, reconstructed the fornix, and minimized inflammation of the ocular surface to a remarkable degree in

patients with severe OSDs. Based on these promising results, novel methods have been developed for the cultivation of allogeneic corneal^{7,8,21} or autologous oral mucosal^{22–25} epithelial cells on a denuded amniotic membrane. Immunologic rejection and increased risk of infection or systemic adverse effects associated with the long-term immunosuppressive therapy accompanying allograft transplantation⁶ encouraged changing to autologous cultivated oral mucosal epithelial transplantation (COMET) in patients with severe OSDs in 2002.^{10,11,23,26}

To clarify the effectiveness, disease-specific outcomes, and safety of COMET, all of the clinical data from all 72 patients that the authors treated with COMET since 2002 were analyzed. The objective of this present study was to summarize the long-term clinical outcomes of 40 of those 72 patients who underwent COMET with the primary objective of visual improvement between June 2002 and December 2008.

Patients and Methods

Patients

Autologous COMET was performed on consecutive patients who were diagnosed with total LSCD based on the complete disappearance of the palisades of Vogt and 360° of conjunctivalization.¹ The COMET treatment protocol was approved by the ethical review board of Kyoto Prefectural University of Medicine, Kyoto, Japan, in 2002. The final decision to perform COMET was made by the university's team of corneal specialists. Before the surgery, written informed consent was obtained from all patients in accordance with the tenets of the Declaration of Helsinki for research involving human subjects. The current retrospective study used an itemized data collection form, and the medical records of all patients who underwent COMET between June 2002 and December 2008 were examined retrospectively. This retrospective study protocol was approved by the ethical review board of Kyoto Prefectural University of Medicine in 2009. In this study, 40 of the 72 patients who underwent COMET were analyzed with the primary objective of visual improvement.

Cell Culture

All of the COMET sheets were prepared at the good manufacturing practices—graded Cell Processing Center at Kyoto Prefectural University of Medicine as previously described.^{23,26} Autologous oral mucosal epithelial cells were obtained from a 6-mm-diameter biopsy specimen obtained from each patient's buccal mucosa, and the cells then were cultured on an amniotic membrane spread on the bottom of a culture insert and were cocultured with mitomycin C-inactivated 3T3 fibroblasts (NIH-3T34; RIKEN Cell Bank, Tsukuba, Japan). The cultured cells were submerged in medium for approximately 1 week and then were exposed to air by lowering the medium level (airlifting) for 1 to 2 days. All amniotic membrane was obtained from caesarean sections according to the preparation method described previously.²³ Although fetal bovine serum initially was used as a culture medium, autologous serum was used in later cultures to reduce the risk of transmitting non-human pathogens.²⁶

Transplantation and Postoperative Management

The surgical procedure (see the Supplemental Video, available at <http://aaojournal.org>) and postoperative management have been described previously.^{24,25} In patients with severe symblepharon or

a large area of bare sclera exposed during surgery, amniotic membrane was transplanted onto the bare sclera to reconstruct conjunctival fornices.¹⁸ In patients with a cataract, phacoemulsification and aspiration plus intraocular lens implantation were performed simultaneously with COMET. No penetrating keratoplasty or deep lamellar keratoplasty was performed simultaneously with COMET. For patients with severe corneal stromal opacity, a 2-step surgical approach was planned, with the first step being COMET and the second step being either penetrating or deep lamellar keratoplasty.²⁵

Systemic corticosteroid (betamethasone, 1 mg/day) and cyclosporine (2 to 3 mg/kg daily) were administered to prevent postoperative inflammation and immunologic response and then were tapered, depending on the clinical findings. Dexamethasone (0.1%) and antibiotic eye drops were instilled 4 times daily. Dry-eye patients were administered artificial tears. A therapeutic soft contact lens was used for at least 1 month to protect transplanted epithelium from mechanical ablation.

Postoperative Follow-up and Outcomes

Best-corrected visual acuity (BCVA) was converted to the logarithm of the minimum angle of resolution (logMAR). Ocular surface conditions including corneal appearance (epithelial defects, clinical conjunctivalization, neovascularization, opacification, keratinization, and symblepharon) were graded by at least 2 ophthalmologists (C.S., T.I., and T.N.) on a scale from 0 to 3 according to their severity, in accordance with a previously reported grading system.²⁷ Severe OSDs are characterized by an associated loss of conjunctival stem cells, and the severity of conjunctival involvement affects the visual prognosis. Therefore, findings on upper and lower fornix shortening were added to evaluate the grade of conjunctival appearance. Fornix shortening was graded from 0 to 3 based on the following clinical features: normal depth (grade 0), shortened by less than one quarter (grade 1), shortened by one quarter to one half (grade 2), and shortened by more than one half (grade 3). Upper and lower fornix shortenings were graded separately. The sum of each grading score was defined as the ocular surface grading score (maximum, 24).

Each patients logMAR BCVA, ocular surface grading score, and data on adverse events related to COMET or postoperative management were collected from the medical records at these specific time points: before surgery; at the 4th, 12th, and 24th postoperative weeks; and at the last follow-up examination. The primary outcome was the change in logMAR BCVA at the 24th postoperative week. Because other ocular diseases can affect this visual outcome, a secondary outcome, the ocular surface grading score, also was defined.

Statistical Analysis

The change in BCVA and ocular surface grading score from baseline at each visit, except for the last visit, was analyzed using the Wilcoxon signed-rank test in each disease category (SJS, OCP, thermal or chemical injury) except for other diseases. Multivariate stepwise logistic regression analysis was used to determine the factors influencing visual improvement.

This study defined the critical visual improvement rate as the proportion of patients in whom BCVA at the 24th postoperative week had improved to at least 0.01, as a percentage of the patients with a BCVA of less than 0.01 at baseline. Patients with a visual acuity of 0.01 or more can read and walk using vision aids. Thus, an improvement to at least 0.01 indicates a capacity for independence in daily life. If data were missing from the 24th postoperative week, data from follow-up at the last visit were substituted.




Figure 1. Diagram showing flow of study. Seventy-two patients (81 eyes) underwent cultivated oral mucosal epithelial sheet transplantation (COMET) between June 2002 and December 2008, and 40 patients (46 eyes) were analyzed for visual improvement in this study. Both corneal reconstruction and conjunctival fornix reconstruction were carried out in 3 cases, in the same eye in 1 case, and counted separately.

All statistical analyses were conducted at the Translational Research Informatics Center (Kobe, Japan) with the use of SAS software, version 9.1 (SAS Inc, Cary, NC) or JMP software, version 8.2 (SAS Inc). *P* values of less than 0.05 were considered statistically significant.

Results

Patient Characteristics

Between 2002 and 2008, 47 COMETs (46 eyes in 40 patients) were performed on 21 eyes with SJS, 10 eyes with OCP, 7 eyes with thermal or chemical injury, and 9 eyes with other causes of LSCD (Fig 1). Although 23 eyes (48.9%) previously had been treated with ocular surgery, all of these previous treatments had

failed and recurrence of fibrovascular ingrowth on the cornea was observed. Of the 47 surgeries performed, symblepharon and keratinization of the cornea were present in 37 eyes (78.7%) and 10 eyes (21.3%), respectively, thus indicating that most of the eyes were inflicted with end-stage severe OSDs (Table 1).

Outcomes of Cultivated Oral Mucosal Epithelial Sheet Transplantation

Cultivated autologous oral mucosal epithelial sheets were generated successfully from all patients. In all patients, COMET was performed successfully and no epithelial damage was observed during surgery. Cultivated oral mucosal epithelial sheet transplantation was combined with amniotic membrane transplantation in 34 (72%) of the 47 surgeries and with cataract surgery in 11 eyes (23%; Table 2, available at <http://aojournal.org>). In 10 patients

Table 1. Baseline Characteristics in Patients Who Underwent Autologous Cultivated Oral Mucosal Epithelial Transplantation

	Total	Stevens-Johnson Syndrome	Ocular Pemphigoid	Thermal/Chemical Injury	Others
No. of COMETs	47	21	10	7	9
Age (yrs)					
Median	57.0	43.0	73.5	50.0	34.0
Range	9–86	14–71	62–86	27–79	9–75
Duration of illness (yrs)					
Median	12.3	17.9	3.5	6.0	5.08
Range	0.3–40.0	3.0–38.0	0.3–15.0	0.5–24.0	0.5–40.0
Prior ocular surgery (%)	23 (48.9)	9 (42.9)	4 (40.0)	3 (42.9)	7 (77.8)
Planned 2-step operations (%)	10 (21.3)	2 (9.5)	0 (0)	6 (85.7)	2 (22.2)
Symblepharon (%)	37 (78.7)	18 (85.7)	10 (100.0)	6 (85.7)	3 (33.3)
Keratinization (%)	10 (21.3)	8 (38.1)	1 (10.0)	0 (0)	1 (11.1)
Preoperative visual acuity*					
Median	2.40	2.4	2.70	2.70	2.40
Range	1.11–3.00	1.40–3.00	1.52–2.70	1.22–2.70	1.10–2.70
Preoperative ocular surface grading score					
Median	14.0	15.0	17.0	13.0	8.0
Range	5.0–21.0	8.0–21.0	10.0–21.0	7.0–17.0	5.0–19.0

COMET = autologous cultivated oral mucosal epithelial transplantation.

*Logarithm of the minimum angle of resolution units.

with severe corneal stromal opacity, a 2-step surgical approach was planned, with COMET followed by penetrating keratoplasty or deep lamellar keratoplasty.²⁵ Three patients underwent the second surgery before the 24th postoperative week and 5 patients underwent the surgery after the 24th week, but 2 patients did not undergo the second surgery during the study period.

The median preoperative logMAR BCVA was 2.40, and in 31 of the eyes (66%), visual acuity was poorer than 20/2000 (<0.01 , logMAR >2). The median preoperative ocular surface grading score was 18.0 (range, 5 to 21). The median patient follow-up period with observation of the primary outcome was 28.7 months after transplantation (range, 6.2 to 85.6 months). Because of heterogeneous etiologic mechanisms, the outcomes in each category are described separately.

Disease-Specific Outcomes

Stevens-Johnson Syndrome. Seventeen patients with SJS underwent COMET (Table 2, available at <http://aaojournal.org>). The BCVA improved significantly at 4, 12, and 24 weeks after surgery ($P = 0.0005$, $P = 0.0010$, and $P = 0.0117$, respectively; Fig 2A). The ocular surface grading score also improved significantly at 4, 12, and 24 weeks after surgery ($P < 0.0001$ for each time point; Fig 2B).

Ocular Cicatricial Pemphigoid. Nine patients (10 eyes) with OCP underwent COMET (Table 1). All 9 patients were older than 60 years, older than many of the patients in this study with other diseases (Table 2, available at <http://aaojournal.org>). The BCVA was improved significantly at the 4th postoperative week ($P = 0.0156$), but this improvement later disappeared (Fig 2A). In contrast, improvement of the ocular surface grading score was sustained throughout the follow-up period ($P = 0.0020$, $P = 0.0020$, and $P = 0.0078$, respectively; Fig 2B).

Thermal or Chemical Injury. Seven patients (7 eyes) with thermal or chemical injury underwent COMET. Their BCVA did not change until the 24th postoperative week; however, the ocular surface grading score in all 7 patients improved significantly ($P = 0.0156$ for each visit; Fig 2A, B). Although penetrating keratoplasty or deep lamellar keratoplasty surgery was planned for 6 of these 7 patients, only 2 patients underwent this second surgery

before the 24th postoperative week visit. Both the BCVA and ocular surface score improved in all 7 patients after the planned surgeries were performed.

Others. Eight other patients underwent COMET: 3 with idiopathic stem cell deficiency, 1 with radiation keratopathy, 1 with graft-versus-host disease, 1 with congenital aniridia, 1 with Salzmanns corneal degeneration, and 1 with drug-toxicity-induced LSCD. In 6 of these 8 patients, BCVA was improved significantly; however, no improvement was seen in 2 of these patients (Table 2, available at <http://aaojournal.org>; Fig 2A). The 2 patients with no improvement had severe dryness on the ocular surface and had the highest ocular surface grading score in this group. In addition, severe lagophthalmos was present in the 1 patient with radiation keratopathy because of severe lid scarring after irradiation for retinoblastoma. One other patient with graft-versus-host disease had longstanding inflammation on the ocular surface. In both of these 2 cases, keratinization and symblepharon progressed gradually after COMET. Six patients who demonstrated improvement had a low preoperative ocular surface grading score, yet this score was improved considerably in all patients at the 24th postoperative week (Table 2; Fig 2B).

Critical Visual Improvement Rate

The critical visual improvement rate for SJS, OCP, and thermal or chemical injury was 50.0% (7/14), 42.9% (3/7), and 20.0% (1/5), respectively, although the second planned surgery²⁵ (penetrating or deep lamellar keratoplasty) had yet to be carried out at the 24th postoperative week in 7 of 10 eyes. The clinical observations on both preoperative and postoperative anterior segment slit-lamp photographs are shown in Figure 3 (available at <http://aaojournal.org>). All patients demonstrated an improvement in their BVCA to 0.01 or more, from a baseline condition of vision loss.

Factors Influencing Visual Improvement

Multivariate stepwise logistic regression analysis was used to estimate the factors influencing postoperative visual acuity after COMET, and the following factors were chosen as variables:




Figure 2. Graphs showing preoperative (Pre) and postoperative clinical outcomes. **A,** Best-corrected visual acuity (BCVA). The BCVA values for each patient are shown grouped according to the cause of corneal dysfunction: Stevens-Johnson syndrome (SJS), ocular cicatricial pemphigoid (OCP), thermal or chemical injury, and others. The change in BCVA from baseline at each visit, except for the last visit, was analyzed using the Wilcoxon signed-rank test in each disease category (SJS, OCP, thermal or chemical injury) except others. Open circles represent cases treated with autologous cultivated oral mucosal epithelial transplantation (COMET) only. Triangles represent cases treated with a planned 2-step surgical combination of COMET followed by penetrating keratoplasty (PK) or deep lamellar keratoplasty (DLKP). Open triangles are before the second operation, and closed triangles are after the second operation. The horizontal line within each box represents the median value, the bottom and top lines of the box represent the 25th and 75th percentiles, respectively, and the horizontal lines below and above the box represent the lowest and highest values, respectively (or are located 1.5 times the interquartile range away from the box). * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$ (2-sided). **B,** Total ocular surface grading score. Ocular surface grading scores for each patient were calculated and are shown according to each cause of corneal dysfunction: SJS, OCP, thermal or chemical injury, and others. Scores for 8 components of the ocular surface were calculated by the grading system. The total scores before surgery and at the 4th, 12th, and 24th postoperative weeks and at last follow-up examination were calculated. Open circles represent patients treated with COMET only. Triangles represent patients treated with a planned 2-step surgical combination of COMET followed by PK or DLKP. Open triangles are before the second operation, and closed triangles are after the second operation. The change in ocular surface grading score from baseline at each visit, except for the last visit, was analyzed using the Wilcoxon signed-rank test in each disease category (SJS, OCP, thermal or chemical injury) except others. The horizontal line within each box represents the median value, the bottom and top lines of the box represent the 24th and 75th percentiles, respectively, and the horizontal lines below and above the box represent the lowest and highest values, respectively (or are located 1.5 times the interquartile range away from the box). * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$ (2-sided). w = weeks.

Table 3. Summary of Adverse Events in Patients Who Underwent Autologous Cultivated Oral Mucosal Epithelial Transplantation

Event	Total	Disease Category			
		Stevens-Johnson Syndrome	Ocular Cicatricial Pemphigoid	Thermal or Chemical Injury	Others
Hepatic dysfunction	1	1			
Drug-induced allergy	1				1
Persistent epithelial defect	16	10	3	2	1
Corneal stromal melting after the epithelial defect	2		1		1
Ocular infection (keratitis, endophthalmitis)	2	2			
Infiltration	3	2	1		
Elevation of IOP resulting from steroid use	4		1	2	1

IOP = intraocular pressure.
No life-threatening serious adverse events were observed.

disease category, patient age, 2-step surgery, combination with amniotic membrane transplantation, combination with cataract surgery, preoperative logMAR BCVA, and the 8 components of the ocular surface grading system. Corneal neovascularization and symblepharon were found to be correlated significantly with logMAR improvement at the 24th postoperative week ($P = 0.0023$ and $P = 0.0173$, respectively). Visual prognosis was better in the eyes with slight symblepharon than in the eyes with severe symblepharon. In contrast, it was better in the eyes with severe neovascularization than in the eyes with slight neovascularization.

Adverse Events

A summary of the adverse events in the 40 patients who underwent COMET is shown in Table 3. No life-threatening serious adverse events were observed in any of the transplantations. Systemically, moderate liver dysfunction occurred in 1 patient (2.5%; 95% confidential interval [CI], 0.1 to 13.2), but liver function normalized after the discontinuation of systemic drugs.

Postoperative persistent epithelial defects occurred in the eyes of 16 (40.0%) of the 40 patients (95% CI, 24.9 to 56.7), and rather frequently in the SJS eyes (60.0% of SJS patients). Corneal stromal melting after the epithelial defect occurred in 2 patients (5.0%; 95% CI, 0.6 to 16.9), but neither eye became perforated. All of these patients were treated successfully. Slight to moderate corneal infection occurred in 2 patients (5.0%; 95% CI, 0.6 to 16.9); however, both patients healed without scarring. A suspected infection with cell infiltration on the cornea²⁸ occurred in 3 patients, yet in each patient, it healed within 1 week after receiving a topical instillation of antibiotics. Although a slight elevation of intraocular pressure resulting from steroid use was seen in 4 patients (10.0%; 95% CI, 2.8 to 23.7), this returned to the normal range after reduction of the steroid dose. None of the patients required glaucoma surgery.

Discussion

Severe OSD has proven to be one of the most difficult disorders to treat, and for many patients, vision loss is the end result.^{29,31} Keratoprosthesis surgery is one possible way to obtain visual improvement in end-stage severe OSDs; however, serious complications such as endophthalmitis,

glaucoma, and tissue melting can arise, especially in SJS or OCP, and can lead to permanent vision loss.^{32,33}

At the beginning of 2002, the authors performed ocular surface reconstruction using tissue-engineered autologous oral mucosal epithelial sheets for the first time.²³ In a report of the initial results from the first 12 cases, the successful long-term engraftment of cultivated oral mucosal cells and their transparency was confirmed.²⁴ Since then, COMET has been used to treat OSD patients, with careful consideration of the surgical indications.^{24–26,34} The authors performed 86 COMET operations between 2002 and the end of 2008 for visual improvement, epithelialization of persistent epithelial defects, or conjunctival reconstruction (Fig 1).

In this study, the clinical efficacy and safety of 47 COMETs were evaluated for visual improvement. In 23 eyes (48.9%), previous ocular surgery such as corneal transplantation or amniotic membrane transplantation already had been carried out unsuccessfully at other hospitals. Symblepharon was involved in 37 eyes (78.7%) and keratinization was involved in 10 eyes (21.3%). Symblepharon indicates conjunctival involvement, and pathologic keratinization means that the eye is at the end stage of a severe OSD with chronic inflammation.^{3,35} Most of these eyes had severe tear deficiency, which is an important prognostic parameter for surgical outcome.³⁶ Although such eyes commonly are considered to have contraindications for ocular surface reconstruction, COMET offered substantial visual improvement even for patients with such advanced disease.

In more than half of the eyes, preoperative visual acuity was limited to counting fingers or hand movements. It is striking that such patients were able to come to the hospital without assistance during the 24 weeks after undergoing COMET. For this reason, critical visual improvement rate is proposed as a clear end point for measuring surgical outcome. Considering that most of the eyes in this study were at the end stage of a severe OSD, these results are very favorable and encouraging.

In this study, the preoperative ocular surface grading score was higher (more diseased) in patients with SJS and OCP than in those with thermal or chemical injuries or other

diseases. It should be noted that visual improvement was statistically significant in SJS. In contrast, visual acuity was not improved at the 24th postoperative week in patients with thermal or chemical injury, despite the improvement in total ocular surface grading score. The corneal stroma was damaged severely in most cases of thermal or chemical injury, and such patients obtained visual improvement after undergoing the planned second surgery with penetrating keratoplasty or deep lamellar keratoplasty. In general, the prognosis of penetrating or deep lamellar keratoplasty alone for severe OSDs is very poor.² However, the findings of this study show that patients with severe OSDs with corneal stromal opacity can obtain visual improvement after undergoing the surgical combination of COMET and penetrating or deep lamellar keratoplasty.

Best-corrected visual acuity was not improved at the 24th postoperative week in patients with OCP, despite significant improvement of the ocular surface grading score. Because OCP is a progressive autoimmune disease, pathologic keratinization or thickening of the epithelium occurred readily after COMET, thus disrupting visual acuity.

No serious systemic complications occurred in any of the patients. The incidence of postoperative persistent epithelial defects was relatively high, yet still similar to or lower than that reported with other therapies.^{6,36–38} Considering that corneal perforation is a common complication after corneal reconstruction in severe OSDs,^{38–40} it is noteworthy that no perforation occurred and that none of the eyes demonstrated vision loss after COMET. Ocular surface reconstruction with a combination of COMET and amniotic membrane transplantation was needed to achieve the total replacement of cicatrized tissue. Because cultured epithelial cells on amniotic membrane attach to a basement membrane with hemidesmosomes,²² these cells can avoid being dropped off and actually survive, regardless of an unstable tear film and the mechanical trauma of blinking. When used as the substrate for oral mucosal cells, amniotic membrane may play a role in protecting the cornea from melting.

Multivariate stepwise logistic regression analysis showed that symblepharon and neovascularization are prognostic factors for visual improvement. Although disease-specific outcomes showed different patterns as described above, disease category was not related to visual prognosis. However, the sample size may be too small to perform such subgroup analyses. Multivariate stepwise logistic regression analysis also was performed for all 86 surgeries to determine the factors influencing persistent epithelial defects. Having SJS and a very low tear meniscus were the prognostic factors for persistent epithelial defects ($P = 0.0204$ and $P = 0.0388$, respectively). Thus, it is likely that both the disease category and dryness of the eye influenced the prognosis.

Long-term ocular surface appearance was examined in 17 of the 72 patients with a follow-up of more than 3 years.³⁴ No further surgery was carried out in these patients. The ocular surface in each case became stable from 6 months after COMET, with a gradual reduction in corneal neovascularization,³⁴ as others have reported in similar studies.⁴⁰ Moreover, postoperative invasion of conjunctival tissue and symblepharon formation was inhibited significantly for more than 3 years.³⁴ Deep lamellar or penetrating

keratoplasty was performed for the patients with corneal stromal opacity after the stabilization of the ocular surface (as the second step of a 2-step surgical combination), in most cases from 24 weeks after COMET.

After COMET, upper or lower eyelid cicatricial entropion with various degrees of tarsal-plate atrophy sometimes was found. In cases with an eyelid abnormality, eyelid surgery was performed to correct entropion, trichiasis, or lagophthalmos. Eyelid condition is an important factor for maintaining ocular surface stability, as well as for avoiding complications such as infection or persistent epithelial defects.

In conclusion, the findings of this retrospective study showed that long-term visual improvement can be obtained in end-stage severe OSDs with complete LSCD and that COMET offered substantial visual improvement even for patients with severe tear deficiency. The findings also showed that patients with corneal blindness resulting from severe OSDs such as SJS benefited from critical improvement of visual acuity.

Acknowledgments. The authors thank Dr. Shin Kawamata of the Foundation for Biological Research and Innovation and Dr. Kazunori Takeda, Dr. Hiroaki Kato, Dr. Hiroshi Tanaka, Dr. Yuji Yamamoto, and Dr. Takahiro Yamawaki of Kyoto Prefectural University of Medicine for data collection.

References

1. Kinoshita S, Adachi W, Sotozono C, et al. Characteristics of the human ocular surface epithelium. *Prog Retin Eye Res* 2001;20:639–73.
2. Tugal-Tutkun I, Akova YA, Foster CS. Penetrating keratoplasty in cicatrizing conjunctival diseases. *Ophthalmology* 1995;102:576–85.
3. Kawasaki S, Nishida K, Sotozono C, et al. Conjunctival inflammation in the chronic phase of Stevens-Johnson syndrome. *Br J Ophthalmol* 2000;84:1191–3.
4. Wall V, Yen MT, Yang MC, et al. Management of the late ocular sequelae of Stevens-Johnson syndrome. *Ocul Surf* 2003;1:192–201.
5. Kenyon KR, Tseng SC. Limbal autograft transplantation for ocular surface disorders. *Ophthalmology* 1989;96:709–22.
6. Tsubota K, Satake Y, Kaido M, et al. Treatment of severe ocular-surface disorders with corneal epithelial stem-cell transplantation. *N Engl J Med* 1999;340:1697–703.
7. Koizumi N, Inatomi T, Suzuki T, et al. Cultivated corneal epithelial transplantation for ocular surface reconstruction in acute phase of Stevens-Johnson syndrome. *Arch Ophthalmol* 2001;119:298–300.
8. Koizumi N, Inatomi T, Suzuki T, et al. Cultivated corneal epithelial stem cell transplantation in ocular surface disorders. *Ophthalmology* 2001;108:1569–74.
9. Nakamura T, Inatomi T, Sotozono C, et al. Successful primary culture and autologous transplantation of corneal limbal epithelial cells from minimal biopsy for unilateral severe ocular surface disease. *Acta Ophthalmol Scand* 2004;82:468–71.
10. Kinoshita S, Koizumi N, Nakamura T. Transplantable cultivated mucosal epithelial sheet for ocular surface reconstruction. *Exp Eye Res* 2004;78:483–91.
11. Kinoshita S, Koizumi N, Sotozono C, et al. Concept and clinical application of cultivated epithelial transplantation for ocular surface disorders. *Ocul Surf* 2004;2:1–33.
12. Nishida K, Yamato M, Hayashida Y, et al. Corneal reconstruction with tissue-engineered cell sheets composed of autologous oral mucosal epithelium. *N Engl J Med* 2004;351:1187–96.

13. Nakamura T, Inatomi T, Sotozono C, et al. Transplantation of autologous serum-derived cultivated corneal epithelial equivalents for the treatment of severe ocular surface disease. *Ophthalmology* 2006;113:1765–72.
14. Ang LP, Sotozono C, Koizumi N, et al. A comparison between cultivated and conventional limbal stem cell transplantation for Stevens-Johnson syndrome. *Am J Ophthalmol* 2007;143:178–80.
15. Rama P, Matuska S, Paganoni G, et al. Limbal stem-cell therapy and long-term corneal regeneration. *N Engl J Med* 2010;363:147–55.
16. Tseng SC, Espana EM, Kawakita T, et al. How does amniotic membrane work? *Ocul Surf* 2004;2:177–87.
17. Tseng SC, Prabhasawat P, Lee SH. Amniotic membrane transplantation for conjunctival surface reconstruction. *Am J Ophthalmol* 1997;124:765–74.
18. Solomon A, Espana EM, Tseng SC. Amniotic membrane transplantation for reconstruction of the conjunctival fornices. *Ophthalmology* 2003;110:93–100.
19. Tsubota K, Satake Y, Ohyama M, et al. Surgical reconstruction of the ocular surface in advanced ocular cicatricial pemphigoid and Stevens-Johnson syndrome. *Am J Ophthalmol* 1996;122:38–52.
20. Tsai RJ, Li LM, Chen JK. Reconstruction of damaged corneas by transplantation of autologous limbal epithelial cells. *N Engl J Med* 2000;343:86–93.
21. Koizumi N, Inatomi T, Quantock AJ, et al. Amniotic membrane as a substrate for cultivating limbal corneal epithelial cells for autologous transplantation in rabbits. *Cornea* 2000;19:65–71.
22. Nakamura T, Endo K, Cooper LJ, et al. The successful culture and autologous transplantation of rabbit oral mucosal epithelial cells on amniotic membrane. *Invest Ophthalmol Vis Sci* 2003;44:106–16.
23. Nakamura T, Inatomi T, Sotozono C, et al. Transplantation of cultivated autologous oral mucosal epithelial cells in patients with severe ocular surface disorders. *Br J Ophthalmol* 2004;88:1280–4.
24. Inatomi T, Nakamura T, Koizumi N, et al. Midterm results on ocular surface reconstruction using cultivated autologous oral mucosal epithelial transplantation. *Am J Ophthalmol* 2006;141:267–75.
25. Inatomi T, Nakamura T, Kojyo M, et al. Ocular surface reconstruction with combination of cultivated autologous oral mucosal epithelial transplantation and penetrating keratoplasty. *Am J Ophthalmol* 2006;142:757–64.
26. Ang LP, Nakamura T, Inatomi T, et al. Autologous serum-derived cultivated oral epithelial transplants for severe ocular surface disease. *Arch Ophthalmol* 2006;124:1543–51.
27. Sotozono C, Ang LP, Koizumi N, et al. New grading system for the evaluation of chronic ocular manifestations in patients with Stevens-Johnson syndrome. *Ophthalmology* 2007;114:1294–302.
28. Sotozono C, Inagaki K, Fujita A, et al. Methicillin-resistant *Staphylococcus aureus* and methicillin-resistant *Staphylococcus epidermidis* infections in the cornea. *Cornea* 2002;21:S94–101.
29. Samson CM, Nduaguba C, Baltatzis S, Foster CS. Limbal stem cell transplantation in chronic inflammatory eye disease. *Ophthalmology* 2002;109:862–8.
30. Solomon A, Ellies P, Anderson DF, et al. Long-term outcome of keratolimbal allograft with or without penetrating keratoplasty for total limbal stem cell deficiency. *Ophthalmology* 2002;109:1159–66.
31. Sotozono C, Ueta M, Koizumi N, et al. Diagnosis and treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis with ocular complications. *Ophthalmology* 2009;116:685–90.
32. Khan B, Dudenhofer EJ, Dohlman CH. Keratoprosthesis: an update. *Curr Opin Ophthalmol* 2001;12:282–7.
33. Liu C, Okera S, Tandon R, et al. Visual rehabilitation in end-stage inflammatory ocular surface disease with the osteo-odonto-keratoprosthesis: results from the UK. *Br J Ophthalmol* 2008;92:1211–7.
34. Nakamura T, Takeda K, Inatomi T, et al. Long-term results of autologous cultivated oral mucosal epithelial transplantation in the scar phase of severe ocular surface disorders. *Br J Ophthalmol* 2011;95:942–6.
35. Tanioka H, Kawasaki S, Sotozono C, et al. The relationship between preoperative clinical scores and immunohistological evaluation of surgically resected tissues in chronic severe ocular surface diseases. *Jpn J Ophthalmol* 2010;54:66–73.
36. Shimazaki J, Shimmura S, Fujishima H, Tsubota K. Association of preoperative tear function with surgical outcome in severe Stevens-Johnson syndrome. *Ophthalmology* 2000;107:1518–23.
37. Turgeon PW, Nauheim RC, Roat MI, et al. Indications for keratoepithelioplasty. *Arch Ophthalmol* 1990;108:233–6.
38. Ma DH, Kuo MT, Tsai YJ, et al. Transplantation of cultivated oral mucosal epithelial cells for severe corneal burn. *Eye (Lond)* 2009;23:1442–50.
39. Shimazaki J, Aiba M, Goto E, et al. Transplantation of human limbal epithelium cultivated on amniotic membrane for the treatment of severe ocular surface disorders. *Ophthalmology* 2002;109:1285–90.
40. Satake Y, Higa K, Tsubota K, Shimazaki J. Long-term outcome of cultivated oral mucosal epithelial sheet transplantation in treatment of total limbal stem cell deficiency. *Ophthalmology* 2011;118:1524–30.

Footnotes and Financial Disclosures

Originally received: March 10, 2012.

Final revision: July 17, 2012.

Accepted: July 18, 2012.

Available online: October 16, 2012.

Manuscript no. 2012-353.

¹ Department of Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Japan.

² Translational Research Informatics Center, Foundation for Biomedical Research and Innovation, Kobe, Japan.

Presented at: American Academy of Ophthalmology Annual Meeting, October 2011, Orlando, Florida.

Financial Disclosure(s):

The author(s) have no proprietary or commercial interest in any materials discussed in this article.

Supported in part by a Grant-in-aid for Scientific Research from the Japanese Ministry of Health, Labor and Welfare, Tokyo, Japan; and a Research Grant of the Coordination, Support and Training Program for Translational Research from the Japanese Ministry of Education, Culture, Sports, Science and Technology, Tokyo, Japan.

Correspondence:

Chie Sotozono, MD, PhD, Department of Ophthalmology, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Hirokoji-agaru, Kawaramachi-dori, Kamigyo-ku, Kyoto 602-0841, Japan. E-mail: csotozon@koto.kpu-m.ac.jp.

Research Article

***In Silico* Risk Assessment of HLA-A*02:06-Associated Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Caused by Cold Medicine Ingredients**

Hideto Isogai,¹ Hiroko Miyadera,² Mayumi Ueta,³ Chie Sotozono,³ Shigeru Kinoshita,³ Katsushi Tokunaga,² and Noriaki Hirayama¹

¹Basic Medical Science and Molecular Medicine, Tokai University School of Medicine, 147 Shimokasuya, Isehara, Kanagawa 259-1143, Japan

²Department of Human Genetics, School of International Health, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan

³Department of Ophthalmology, Kyoto Prefectural University of Medicine, Hirokoji Kawaramachi, Kamigyo-ku, Kyoto 602-0841, Japan

Correspondence should be addressed to Noriaki Hirayama; hirayama@is.icc.u-tokai.ac.jp

Received 12 July 2013; Revised 4 September 2013; Accepted 4 September 2013

Academic Editor: Anthony DeCaprio

Copyright © 2013 Hideto Isogai et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe drug hypersensitivities with high mortality. Typical over-the-counter drugs of cold medicines are suggested to be causative. As multiple ingredients are generally contained in cold medicines, it is of particular interest to investigate which ingredients are responsible for SJS/TEN. However, experimental examination of causal relationships between SJS/TEN and a particular drug molecule is not straightforward. Significant association between HLA-A*02:06 and SJS/TEN with severe ocular surface complications has been observed in the Japanese. In the present study, we have undertaken *in silico* docking simulations between various ingredients contained in cold medicines available in Japan and the HLA-A*02:06 molecule. We use the composite risk index (CRI) that is the absolute value of the binding affinity multiplied by the daily dose to assess the potential risk of the adverse reactions. The drugs which have been recognized as causative drugs of SJS/TEN in Japan have revealed relatively high CRI, and the association between SJS/TEN and HLA-A*02:06 has been qualitatively verified. The results have also shown that some drugs whose links to SJS/TEN have not been clinically recognized in Japan show the high CRI and suggested that attention should be paid to their adverse drug reactions.

1. Introduction

Adverse drug reactions (ADRs) are a serious public health problem. Drug hypersensitivity which constitutes a major category of ADRs is typically severe in nature. In particular, Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe drug hypersensitivities with high mortality. Various drugs have been pointed out as causes of SJS/TEN. In addition to certain prescription drugs, typical over-the-counter drugs of cold medicines are suggested to be causative [1, 2]. These reactions often result in severe and

definitive sequelae such as vision loss in some cases [2]. The reported incidence of ocular complications in SJS/TEN is 50–68% [3].

Considering the fact that cold medicines are the most widely used over-the-counter drugs, it is extremely important to know the potential causative ingredients of SJS/TEN. Although nonsteroidal anti-inflammatory drugs which are major ingredients of cold medicines were suggested as causative drugs [2], no systematic studies about drug hypersensitivities of other ingredients have been undertaken. Since it is possible that certain ingredients might cause more severe

TABLE 1: Ingredients contained in popular cold medicines available in Japan. Chinese herbs, vitamins, and lysozyme are excluded from the table.

Drug name	Therapeutic category
Acetaminophen	Analgesic; antipyretic
Ambroxol	Expectorant
Bromhexine	Expectorant; mucolytic
Caffeine	CNS stimulant; respiratory stimulant
Carbinoxamine	Antihistaminic
<i>d</i> -Chlorpheniramine	Antihistaminic
Clemastine	Antihistaminic
Dextromethorphan	Antitussive
Dihydrocodeine	Analgesic (narcotic); antitussive
Ethenzamide	Analgesic
Guaiacol	Expectorant
Guafenesin	Expectorant
Ibuprofen	Anti-inflammatory; analgesic; antipyretic
Isopropamide	Antispasmodic
Loxoprofen (<i>R, S</i>)	Anti-inflammatory; analgesic
Mequitazine	Antihistaminic
<i>d</i> -Methylephedrine	Analeptic
Noscapine	Antitussive
Pseudoephedrine	Decongestant
Tranexamic acid	Hemostatic

adverse reactions, predicting the potential adverse reactions of other ingredients will be undoubtedly beneficial to avoid the latent ADRs.

Significant associations between certain ADRs and specific alleles of human leukocyte antigen (HLA) have been pointed out [4]. Recently, the detailed molecular mechanism underlying the strong association between HLA-B*57 and the hypersensitivity of reverse-transcriptase inhibitor abacavir has been disclosed [5]. The relevant adverse drug reaction is triggered by the strong binding of abacavir into the antigenic peptide binding groove of the HLA molecule. It has been reported that the frequency of carriers of the HLA-A*02:06 antigen is significantly higher among Japanese patients with severe ocular surface complications than in other populations [6]. It is highly possible that the adverse drug reactions associated with HLA-A*02:06 are also triggered by the direct interactions between the causative drug molecules and the HLA molecule.

However, it is generally intractable to ascertain experimentally the causation between a specific drug and an incidence of a particular adverse drug reaction especially in cases where multiple drugs are administered simultaneously such as cold medicines. *In silico* analysis based on the underlying molecular mechanism of the ADRs can be employed as a powerful alternative method in these situations. In this study, *in silico* analysis using docking simulations between various ingredient molecules in cold medicines and the HLA-A*02:06 molecule has been undertaken in order to predict




FIGURE 1: The antigenic-peptide binding groove of HLA-A*02:06 is depicted schematically with the two alpha helices represented by helical lines running horizontally. The white and red alpha spheres calculated in the groove represent hydrophobic and hydrophilic positions, respectively. The binding groove is divided into sites C and N.

what ingredient molecules might cause SJS/TEN through the interactions with HLA-A*02:06.

2. Methods

We examined all ingredients contained in four popular over-the-counter cold medicines available in Japan, that is, Lulu, Pabron, Contac, and Benza Block. The ingredient molecules used in docking simulations are given in Table 1. As Chinese herbs contained in all of these over-the-counter cold medicines are mixtures of various agents whose molecular structures are not fully identified, they are excluded from the docking simulations. Lysozyme and vitamins are also excluded. A software system molecular operating environment (MOE) [7] was used throughout this study and all the calculations were performed on a DELL PC workstation T7500.

The X-ray structure of the HLA-A*02:06 molecule deposited in the Protein Data Bank [8] (PDB ID: 3OXR) was used for docking simulations. It is highly possible that the molecules shown in Table 1 bind to the antigenic-peptide binding groove located between two α helices as in the case of abacavir. Since the groove is relatively wide, we have specified the possible binding sites by use of the alpha site finder function [9] implemented in MOE. Small spheres named alpha spheres shown in Figure 1 correspond to locations of tight atomic packing at the antigenic-peptide binding groove. A site where the alpha spheres are clustered is designated alpha site which is considered to be the potential binding site of drug molecules. Two alpha sites designated sites N and C were identified in the antigenic-peptide binding groove of the HLA-A*02:06 molecule and these two sites were considered in docking simulations. All docking simulations were undertaken by use of software ASEDock [10]. ASEDock based on unique concept of ASE model and ASE score uses the alpha sites for docking the small molecule. Since ASEDock is free from any bias except for shape, it is one of the very robust docking methods. The binding affinity of a drug molecule to the HLA molecule was judged by

TABLE 2: Binding affinities of the ingredients of cold medicines to the antigenic-peptide binding groove of HLA-A*02:06. Composite risk index is calculated by multiplying the maximum daily dose and the absolute value of GBVI/WSA_{dG}.

Drug name	Maximum dose/day (mmol)	GBVI _{dG} * (site N) (kcal/mol)	GBVI _{dG} * (site C) (kcal/mol)	Composite risk index (site N)**	Composite risk index (site C)**	Preferential binding site
Ethenzamide	6.356	-4.966	-5.335	31.565	33.914	C
Acetaminophen	5.954	-4.623	-4.608	27.523	27.438	N
Tranexamic acid	4.771	-5.550	-5.613	26.478	26.776	C
Ibuprofen	2.181	-5.491	-5.720	11.979	12.477	C
Abacavir***	1.789		-6.562		11.740	C
Guaifenesin	1.211	-6.482	-5.820	7.848	7.047	N
Guaiaacolsulfonate	0.991	-4.562	-5.482	4.519	5.430	C
Pseudoephedrine	0.669	-5.581	-5.348	3.736	3.579	N
Caffeine	0.463	-5.333	-5.128	2.471	2.377	N
Loxoprofen	0.168	-6.468	-6.184	1.086	1.038	N
Dextromethorphan	0.130	-6.537	-6.315	0.847	0.819	N
Noscapine	0.116	-7.464	-6.792	0.867	0.789	N
<i>d</i> -Methylephedrine	0.139	-6.029	-5.636	0.838	0.784	N
Ambroxol	0.109	-6.763	-6.247	0.734	0.678	N
Dihydrocodeine	0.060	-5.401	-5.709	0.325	0.343	C
Bromhexine	0.029	-6.602	-5.655	0.192	0.164	N
Carbinoxamine	0.018	-7.616	-6.073	0.140	0.112	N
Isopropamide	0.012	-7.729	-6.102	0.097	0.076	N
<i>d</i> -Chlorpheniramine	0.010	-7.265	-6.690	0.070	0.064	N
Mequitazine	0.012	-7.021	-5.021	0.087	0.062	N
Clemastine	0.003	-7.680	-6.265	0.022	0.018	N

*GBVI_{dG}: GBVI/WSA_{dG}. **Composite risk index: |GBVI/WSA_{dG}| × (maximum daily dose).

***Binding to the HLA-B*57:01 molecule.

scoring functions of GBVI/WSA_{dG} [11] which is considered to express protein-ligand binding free energy.

Redocking simulations were performed using the crystal structure of the complex between abacavir and the HLA-B*57:01 molecule (PDB ID: 3VRI) to assess the appropriateness of using ASEDock for the drug-HLA systems. The root-mean square deviation (rmsd) between nonhydrogen atoms of abacavir in the crystal and docked structures is 0.99 Å. Prediction within rmsd of 2.0 Å is held as the passing standard. The validation clearly indicated that ASEDock can simulate accurately enough the structure and position of the bound abacavir molecule in the crystal structure and the docking algorithm is suitable for the docking simulations of the drug-HLA systems. A superposition of the simulated and experimental structures is shown in Figure 2. The GBVI/WSA_{dG} value is calculated to be -6.56 kcal/mol.

3. Results and Discussion

The binding affinities to both sites are given in Table 2. As the racemates of methylephedrine and chlorpheniramine are used, the optical isomers with higher binding affinities are given in the table. Although the binding affinity to the HLA molecule would play an important role to trigger the following immunological response, the probability of occurrence of the adverse reactions might significantly depend on the dose




FIGURE 2: A superposition of simulated and experimental structures of abacavir. The drug is bound at the antigenic-peptide binding groove of the HLA-B*57:01 molecule. The HLA molecules are depicted schematically. The alpha helix and beta strand are shown by red and yellow tubes, respectively. The drug molecules are depicted by stick models. The carbon atoms of abacavir located by X-ray analysis and docking simulations are colored in cyan and green, respectively. This figure is a cross-eyed stereoscopic drawing.

of the drug. Therefore it may be reasonable to use a composite risk index (CRI) calculated by multiplying the absolute value of the binding affinity by the daily dose together to assess the




FIGURE 3: Cross-eyed stereoscopic drawings of the drugs bound at the antigenic-peptide binding grooves of ADR-associated HLA molecules. The drugs are represented by stick models with carbon atoms and bonds colored in green. The interaction modes of acetaminophen, ibuprofen, and loxoprofen at the peptide-binding groove of the HLA-A*02:06 molecule are shown in (a), (b), and (c), respectively.

potential risk of the adverse reactions. In Table 2, the CRI is given and the drug molecules are sorted by descending order of the CRI calculated from the binding affinity to the site C. The maximum dose of each drug per day in mmol was calculated according to the dose written in each package insert of cold medicines. For comparison, the binding affinity of abacavir to the HLA-B*57 molecule is given. Most of the drugs are preferentially bound at the site N. Drugs with higher CRIs are, however, inclined to bind preferentially at the site C as abacavir.

If we set a CRI threshold of, for example, 1.0 mmol·kcal/mol arbitrarily, nine drugs are judged to be high-risk drugs causing adverse drug reactions through binding to HLA-A*02:06. In Japan, warnings about potential side effects of SJS and TEN are explicitly stated in the ethical drug package inserts of acetaminophen, ibuprofen, and loxoprofen [12]. Cases of SJS/TEN caused by acetaminophen [13], ibuprofen [14], and loxoprofen [15] have been reported, albeit the associations with HLA-A*02:06 have not been noticed. Ethenzamide was reported as a causative drug of SJS in Japan [16]. Since it is highly possible that the SJS caused by these four drugs is associated with HLA-A*02:06, studies to verify the associations are urgently required to understand

the molecular mechanisms of the adverse reactions and find countermeasures against them. As to tranexamic acid, guaifenesin, guaiacol, pseudoephedrine, and caffeine, they are not considered as significant causative drugs of SJS at least in Japan. However, 17, 4, and 2 SJS cases caused by guaifenesin, pseudoephedrine, and caffeine, respectively, have been reported from the FDA [17]. TEN caused by tranexamic acid was reported [18]. Although it is highly possible that these adverse drug reactions are associated with different alleles, rather high CRIs of these drugs imply the involvement of these drugs in SJS/TEN. As comprehensive analysis about causative factors of SJS has not been undertaken, unknown factors might be involved in the SJS cases. Under these circumstance, we believe that SJS-like symptoms caused by drugs with the high CRIs should be monitored carefully.

The drugs with the CRI being lesser than 1.0 have not been noticed as culprit drugs for SJS/TEN at least in Japan. The low incidence of SJS/TEN caused by these drugs in Japan supports that the SJS/TEN associated with HLA-A*02:06 should be mainly determined by CRI. Although certain numbers of SJS cases have been reported on drugs such as demastine, mequitazine and bromhexine from the FDA, the causative alleles in these cases may be different from HLA-A*02:06.

Hypersensitivities against these drugs are described in the ethical drug package inserts in Japan.

Metabolites for each drug molecule have not been fully disclosed yet. It is possible that some of such metabolites rather than the parent drugs would play more important roles in certain cases of ADRs. Therefore further simulation studies including the metabolites will be essential and interesting in the more distant future. Nevertheless, these uncertainties do not preclude the usefulness of the simulation results obtained for the parent drugs in the context of a weight of evidence approach for the time being. The *in silico* risk assessment methodology as used in the present study will certainly play an important role in identifying testing needs, setting testing priorities, and above all attracting our attention to the potential toxicities of the relevant drugs.

The binding modes of acetaminophen, ibuprofen, and loxoprofen at the antigenic peptide-binding groove of the HLA-A*02:06 molecule are illustrated in Figures 3(a), 3(b), and 3(c), respectively. The binding mode of abacavir to the HLA-B*57:01 is shown in Figure 2. In the crystal structure [5], abacavir binds deep across the bottom of the antigen-binding groove of the HLA molecule. Therefore new endogenous peptides can bind on top of the bound abacavir leading to the adverse drug reaction of abacavir. On the other hand, acetaminophen and loxoprofen are bound near the surface of the HLA molecule. Although one end of the ibuprofen molecule is bound to the bottom of the groove, the carboxyl group is exposed on the surface of the HLA molecule. Since the binding modes of these drugs appear different from that of abacavir, it is not clear whether new endogenous peptides can bind on top of the bound drugs. Hence further studies to confirm the molecular mechanisms leading to the ADRs are required.

4. Conclusions

Prompt recovery from SJS/TEN upon withdrawal of the relevant drugs indicates the importance of early diagnosis. However, identification of the culprit drugs is usually intractable especially in the cases where patients take drugs with multiple ingredients such as cold medicines. In these situations, a comprehensive risk assessment taking both of circumstantial evidence and theoretically deduced risk index into account would be helpful. In the present study we have shown that docking simulations between drug molecules and the HLA-A*02:06 molecule can explain the episodes of culprit drugs of SJS/TEN reported so far in Japan. In addition, the present study has pointed out the potential risk of several drugs whose involvement in SJS/TEN has not been explicitly noticed until now. This study urges further investigations of verifying the ADRs of these drugs in detail.

Conflict of Interests

The authors declare that they have no conflict of interests.







Acknowledgment

This work was partly supported by Grant-in-Aid for Scientific Research on Innovative Areas (22133012) from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) for Noriaki Hirayama.













References

- [1] Y. Yamane, M. Aihara, and Z. Ikezawa, "Analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis in Japan from 2000 to 2006," *Allergology International*, vol. 56, no. 4, pp. 419–425, 2007.
- [2] M. Ueta, C. Sotozono, M. Nakano et al., "Association between prostaglandin E receptor 3 polymorphisms and Stevens-Johnson syndrome identified by means of a genome-wide association study," *Journal of Allergy and Clinical Immunology*, vol. 126, no. 6, pp. 1218–1225, 2010.
- [3] W. J. Power, M. Ghoraishi, J. Merayo-Llives, R. A. Neves, and C. S. Foster, "Analysis of the acute ophthalmic manifestations of the erythema multiforme/Stevens-Johnson syndrome/toxic epidermal necrolysis disease spectrum," *Ophthalmology*, vol. 102, no. 11, pp. 1669–1676, 1995.
- [4] P. T. Illing, J. P. Vivian, A. W. Purcell, J. Rossjohn, and J. McCluskey, "Human leukocyte antigen-associated drug hypersensitivity," *Current Opinion in Immunology*, vol. 25, no. 1, pp. 81–89, 2013.
- [5] P. T. Illing, J. P. Vivian, N. L. Dudek et al., "Immune self-reactivity triggered by drug-modified HLA-peptide repertoire," *Nature*, vol. 486, no. 7404, pp. 554–558, 2012.
- [6] M. Ueta, K. Tokunaga, C. Sotozono et al., "HLA class I and II gene polymorphisms in Stevens-Johnson syndrome with ocular complications in Japanese," *Molecular Vision*, vol. 14, pp. 550–555, 2008.
- [7] MOE (Molecular Operating Environment), 2011.01; Chemical Computing Group: Montreal, Quebec, Canada, 2011.
- [8] F. C. Bernstein, T. F. Koetzle, and G. J. B. Williams, "The protein data bank: a computer based archival file for macromolecular structures," *Journal of Molecular Biology*, vol. 112, no. 3, pp. 535–542, 1977.
- [9] P. Labute and M. Santavy, "Locating binding sites in protein structures," *Journal of Chemical Computing Group*, 2007.
- [10] J. Goto, R. Kataoka, H. Muta, and N. Hirayama, "ASEDock-docking based on alpha spheres and excluded volumes," *Journal of Chemical Information and Modeling*, vol. 48, no. 3, pp. 583–590, 2008.
- [11] C. R. Corbeil, C. I. Williams, and P. Labute, "Variability in docking success rates due to dataset preparation," *Journal of Computer-Aided Molecular Design*, vol. 26, no. 6, pp. 775–786, 2012.
- [12] http://www.info.pmda.go.jp/psearch/html/menu_tenpu_base.html.
- [13] A. Khawaja, A. Shahab, and S. A. Hussain, "Acetaminophen induced steven Johnson Syndrome-Toxic epidermal necrolysis overlap," *Journal of the Pakistan Medical Association*, vol. 62, no. 5, pp. 524–527, 2012.
- [14] "Ibuprofen: Stevens-Johnson syndrome," *WHO Drugs Information*, vol. 19, no. 3, pp. 208–209, 2005.
- [15] H. Nagata, T. Harada, Y. Nariai, H. Matsushima, and Y. Yoshimura, "Allergic reaction originated from loxoprofen sodium; Report a case," *Journal of The Japanese Stomatological Society*, vol. 52, no. 2, pp. 67–72, 2003.

- [16] A. Inoue, R. Takebayashi, and A. Shoji, "A case of Stevens-Johnson syndrome due to ethenzamide," *Japanese Journal of Dermatoallergology*, vol. 7, no. 3, pp. 61-64, 1999.
- [17] FDA Adverse Event Reporting System (FAERS), <http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/default.htm>.
- [18] M. P. Irazabal, L. M. Martin, L. A. Gil, and M. A. I. Gastearena, "Tranexamic acid-induced toxic epidermal necrolysis," *The Annals of Pharmacotherapy*, vol. 47, article e16, 2013.



Hindawi
Submit your manuscripts at
<http://www.hindawi.com>





Specific HLA types are associated with antiepileptic drug-induced Stevens–Johnson syndrome and toxic epidermal necrolysis in Japanese subjects

Aim: This preliminary study investigated genomic biomarkers for Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), related to three antiepileptic drugs, zonisamide, phenobarbital and phenytoin. **Patients & methods:** *HLA* class I and *HLA-DRB1* loci were genotyped for Japanese patients with zonisamide-, phenobarbital- or phenytoin-induced SJS/TEN ($n = 12$, 8 and 9, respectively) and for healthy Japanese volunteers ($n = 2878$). **Results:** Carrier frequencies of *HLA-A*02:07* in patients with zonisamide-induced SJS/TEN and in the general Japanese population were 41.7 and 6.81%, respectively. Carrier frequencies of *HLA-B*51:01* in patients with phenobarbital- and phenytoin-induced SJS/TEN and in controls were 75.0, 55.6 and 15.2%, respectively. *HLA-A*02:07* and *HLA-B*51:01*, in a dominant model, were significantly associated with zonisamide- and phenobarbital-induced SJS/TEN, respectively ($P_c = 0.0176$ and 0.0042, respectively). **Conclusion:** Our data suggest that *HLA-A*02:07* and *HLA-B*51:01* are potential biomarkers for zonisamide- and phenobarbital-induced SJS/TEN, respectively, in Japanese individuals.

Original submitted 25 April 2013; Revision submitted 11 September 2013

KEYWORDS: aromatic antiepileptic drug *HLA-A*02:07* *HLA-B*51:01* phenobarbital phenytoin Stevens–Johnson syndrome toxic epidermal necrolysis zonisamide

Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe, life-threatening adverse drug reactions. SJS and TEN are characteristic mucosal disorders and are thought to represent different severities of the same disease [1,2]. The most widely accepted classification for SJS and TEN is based on the size of the skin detachment area, as follows: for SJS, a skin detachment area less than 10% of the body surface area; for a SJS–TEN overlap, from 10 to less than 30% of the body surface area; and for TEN, no less than 30% of the body surface area [1]. In Japan, TEN is defined as a skin detachment area more than 10% of the body surface area [3]. Although the incidence of SJS and TEN is very low, the mortality rates for these diseases are estimated to be 1–5 and 20–30%, respectively [4,5].

Recently, the development of carbamazepine-induced SJS/TEN was shown to involve *HLA-B*15:02* in Southeast Asian patients [6–12] and individuals of Asian descent living in Europe [13], while other phenotypes of carbamazepine-induced cutaneous adverse reactions (CARs), such as hypersensitivity syndrome and maculopapular exanthema, are not associated with *HLA-B*15:02* [11,14]. *HLA-B*15:02* was also reported to be associated with phenytoin- and oxcarbazepine-induced SJS/TEN in Han Chinese and Thai patients [11,15]. For Japanese and Korean patients, although carbamazepine-induced

SJS/TEN shows no significant association with *HLA-B*15:02*, it is significantly associated with *HLA-B*15:11*, which belongs to the same serotype, HLA-B75, as *HLA-B*15:02* [16,17]. In addition, another genetic biomarker, *HLA-A*31:01*, has recently been reported to be strongly associated with carbamazepine-induced SJS/TEN and other types of CARs in both Japanese and Caucasian individuals [18–20]. However, this marker has previously been reported to be associated with hypersensitivity syndrome and maculopapular exanthema caused by carbamazepine in Han Chinese individuals and is not associated with SJS/TEN [14]. Associations between *HLA-B*58:01* and allopurinol-induced severe CARs, including SJS/TEN and hypersensitivity, have been recognized in various ethnic groups, such as Asians [21–24] and Europeans [13].

While the number of genomic biomarkers associated with the onset of CARs has been increasing, genomic biomarkers have only been identified for the limited number of causative drugs mentioned above and for anti-HIV drugs, such as abacavir [25] and nevirapine [26]. Therefore, in the current preliminary study in Japanese patients, we examined biomarkers for SJS/TEN caused by phenytoin, zonisamide or phenobarbital, which are often used for epilepsy treatment in Japan and are known to contribute to the development of SJS/TEN [27].

Nahoko Kaniwa*, Emiko Sugiyama, Yoshiro Saito, Kouichi Kurose, Keiko Maekawa, Ryuichi Hasegawa, Hirokazu Furuya, Hiroko Ikeda, Yukitoshi Takahashi, Masaaki Muramatsu, Masahiro Tohkin, Takeshi Ozeki, Taisei Mushiroya, Michiaki Kubo, Naoyuki Kamatani, Masamichi Abe, Akiko Yagami, Mayumi Ueta, Chie Sotozono, Shigeru Kinoshita, Zenro Ikezawa, Kayoko Matsunaga, Michiko Aihara & the Japan Pharmacogenomics Data Science Consortium

*Author for correspondence:
Division of Medicinal Safety Science,
National Institute of Health Sciences,
1-18-1 Kamiyoga, Setagaya-ku,
Tokyo 158-8501, Japan
Tel.: +81 3 3700 9653
Fax: +81 3 3700 9788
nkaniwa@nihns.go.jp
For a full list of affiliations, please see
pages 1830–1831

Future
Medicine  part of 

Patients & methods

■ Patients

Unrelated Japanese patients who experienced SJS or TEN caused by phenytoin, zonisamide or phenobarbital were recruited from two separate groups: the Japan Severe Adverse Reactions (JSAR) research group and RIKEN. In the JSAR research group, patients were recruited between June 2006 and July 2012 from participating institutions or through a nationwide blood sampling network in Japan operated by the National Institute of Health Sciences in cooperation with: the Ministry of Health, Labour and Welfare; Pharmaceutical and Medical Devices Agency; and Federation of Pharmaceutical Manufacturers' Association of Japan [16]. In RIKEN, patients were registered in BioBank Japan [28]. Both groups applied the same criteria proposed by Bastuji-Garin *et al.* for the diagnosis of SJS/TEN [1]; however, the SJS–TEN overlap was categorized as TEN according to the severity criteria used in Japan in this study [3]. Aromatic antiepileptic drugs that were administered to patients within 2 months before the onset of SJS/TEN were assumed to be causative drugs, although some coadministered drugs could not be excluded as the culprit drugs in some patients (TABLE 1). Potential drug–drug interactions caused by the coadministered drugs were ruled out since we did not find any strong CYP2C9 (for phenytoin and phenobarbital) or CYP3A4 (for zonisamide) inhibitors among them. The other patients' background information, such as demographic characteristics, phenotypes of adverse reactions, antiepileptic drugs administered within 2 months before the onset of SJS/TEN and primary diseases are also summarized in TABLE 1. Nine patients had phenytoin-related SJS/TEN. Twelve patients had zonisamide-related SJS/TEN; two of these patients were included in our previous study [16], and another patient (P7) also received phenytoin and was included in the association studies for phenytoin-induced SJS/TEN. Eight patients had phenobarbital-related SJS/TEN, one of whom (P5) had also received phenytoin and was included in the association studies for phenytoin-induced SJS/TEN. For the control group, healthy Japanese volunteers living in Japan were recruited by the Japan Pharmacogenomics Data Science Consortium (JPDSC). Control data obtained from volunteers from Okinawa prefecture (the southernmost islands of Japan) were excluded as principal component analysis by EIGENSOFT ver 4.0 (Helix Systems, MD, USA) using 332,535 SNPs obtained

from a genome-wide association study using Illumina Human Omni2.5 BeadChip (Illumina, Inc., CA, USA) showed that subjects from Okinawa prefecture were separated from subjects from other regions in Japan, and also because none of the patients in this study were from hospitals in Okinawa prefecture. We used data obtained from 2878 healthy Japanese volunteers as control data. The ethics committees of the participating institutions approved this study. Written informed consent was obtained from each subject.

■ HLA typing

For the JSAR research group, high-resolution *HLA* typing was performed with a sequence-based method using SeCore A, SeCore B, SeCore C and SeCore DRB1 Locus Sequencing Kits (Invitrogen Corp., WI, USA) and ABI 3730 and 3130 DNA sequencers (Applied Biosystems, CA, USA). *HLA* types were estimated using the Assign SBT or Assign ATF software (version 3.2.7b and version 1.0.2.41, respectively; Conexio Genomics, Western Australia, Australia). For RIKEN and JPDSC, high-resolution *HLA* typing was performed using *HLA*-typing kits (WAKFlow, Hiroshima, Japan; or LAB-Type SSO, One Lambda, CA, USA), which are based on PCR sequence-specific oligonucleotide probes coupled with multiple analyte profiling (xMAP) technology (Luminex System; Luminex Corporation, TX, USA). Haplotype analysis for control subjects was conducted using LDSUPPORT [29] modified for multiallelic data, and frequencies for individual haplotypes were counted.

■ Statistical analysis

A total of 17 and 14 *HLA* genotypes were detected in multiple patients in the phenytoin and phenobarbital studies, respectively. For these *HLA* genotypes, frequencies in the SJS/TEN groups were compared with those of controls using a dominant genotyping model, and p-values were corrected for multiplicity of testing by the *HLA* genotype numbers compared in individual studies (Bonferroni's correction). In the zonisamide study, frequencies of 21 *HLA* genotypes detected in multiple patients and a haplotype were compared, and p-values were corrected according to the total number (22) of comparisons. For a control group, we used healthy Japanese volunteers rather than patients tolerant to antiepileptic drugs as the incidence of SJS/TEN in Japanese individuals is very low (~3–3.5

Table 1. Backgrounds of Japanese patients with antiepileptic drug-induced Stevens–Johnson syndrome/toxic epidermal necrolysis and their four-digit HLA types.

Patient ID	ADR phenotype	Aromatic antiepileptics administered	Sex/age (years)	Primary disease	Period of latency (days)	Potential other causative drugs [†]	HLA-A	HLA-B	HLA-C	HLA-DRB1
P1	SJS	PHT	M/8	Rasmussen syndrome	11	Gabapentin	24:02/26:03	40:01/51:01	03:04/14:02	09:01/11:01
P2	TEN	PHT	M/4	Intractable epilepsy	16	None	26:01/31:01	44:03/51:01	14:02/14:03	13:02/14:03
P3	SJS	PHT	M/5	Epilepsy	15	None	11:01/24:02	55:04/67:01	03:03/07:02	09:01/15:01
P4	TEN	PHT	F/73	Epilepsy	5	Tazobactam Piperacillin sodium	26:01/26:02	40:01/51:01	01:02/03:04	04:05/14:05
P5	TEN	PHT/PB	F/41	Unavailable	~12	None	11:01/24:20	51:01/55:02	01:02/15:02	04:05/15:01
P6	SJS	PHT	M/67	Unavailable	30	Minocycline hydrochloride Tiapride hydrochloride	02:07/24:02	40:01/46:01	01:02/07:02	08:03/08:03
P7	SJS	PHT/ZNS	F/31	Symptomatic epilepsy	16	Sodium valproate	02:01/02:01	15:18/38:02	07:02/08:01	11:01/13:02
P8	TEN	PHT	F/64	Convulsions after γ -knife treatment	1	None	02:01/24:02	15:01/51:01	04:01/14:02	08:03/09:01
P9	TEN	PHT	F/56	Depression	16	Sodium valproate	11:01/11:01	15:01/54:01	01:02/04:01	04:05/04:06
P101	SJS	ZNS	F/71	Symptomatic epilepsy after brain infarction	21	Omeprazole Candesartan cilexetil	31:01/31:01	40:02/51:01	03:04/14:02	08:02/09:01
P102	SJS	ZNS	F/57	Symptomatic epilepsy after surgery	8	None	02:07/26:01	40:03/46:01	01:02/03:04	08:03/15:02
P103	SJS	ZNS	M/25	Epilepsy	20	None	02:07/31:01	13:01/46:01	01:02/03:03	08:03/12:02
P104	TEN	ZNS/CBZ	M/17	Epilepsy	33	Amoxicillin hydrate	02:07/31:01	46:01/56:01	01:02/04:01	08:03/09:01

[†]Drugs other than aromatic antiepileptics that were coadministered no more than 2 months prior to the onset of SJS/TEN.

ADR: Adverse drug reaction; CBZ: Carbamazepine; F: Female; M: Male; P: Patient; PB: Phenobarbital; PHT: Phenytoin; SJS: Stevens–Johnson syndrome; TEN: Toxic epidermal necrolysis; ZNS: Zonisamide.